S, P., S, W., AM, B., J, O., LS, S., E, B., . . . L, V. (2016). Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: Results from a Phase II, single-arm, multicenter study. Dove Medical Press.
Cita Chicago Style (17a ed.)S, Puhalla, Wilks S, Brufsky AM, O'Shaughnessy J, Schwartzberg LS, Berrak E, Song J, y Vahdat L. Clinical Effects of Prior Trastuzumab on Combination Eribulin Mesylate Plus Trastuzumab as First-line Treatment for Human Epidermal Growth Factor Receptor 2 Positive Locally Recurrent or Metastatic Breast Cancer: Results from a Phase II, Single-arm, Multicenter Study. Dove Medical Press, 2016.
Cita MLA (8a ed.)S, Puhalla, et al. Clinical Effects of Prior Trastuzumab on Combination Eribulin Mesylate Plus Trastuzumab as First-line Treatment for Human Epidermal Growth Factor Receptor 2 Positive Locally Recurrent or Metastatic Breast Cancer: Results from a Phase II, Single-arm, Multicenter Study. Dove Medical Press, 2016.